| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 176.7 | 179.5 |
| Profit before tax | 28.8 | 9.5 |
| Net income | 28.5 | 5.4 |
| EPS (diluted, $ a share) | $0.70 | $0.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +425.1% |
|---|---|
| Revenue, year on year | -1.6% |
| Operating margin | 12.6% |
10-Q filed with the SEC, NASDAQ: PCRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pacira BioSciences, Inc.: key numbers
- Share price
- $36.48Close, Nov 16
- Market cap
- $1.46B
- Shares outstanding
- 40.09MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pacira BioSciences, Inc.
All →Pacira BioSciences M&A Deal with Viatris Inc.
Pacira BioSciences, Inc. completed its merger with Viatris Inc. on November 17, 2026, following a tender offer where Viatris acquired all outstanding shares for $36.50 per share in cash. As a result of the transaction, Pacira has become a wholly owned subsidiary of Viatris and entered into supplemental indentures to address its outstanding 2.125% Convertible Senior Notes due 2029.
- Counterparty
- Viatris Inc.
Pacira BioSciences Court & Legal Update
The U.S. Court of Appeals for the Ninth Circuit partially reversed a lower court ruling, determining that Pacira BioSciences owes royalties to the Research Development Foundation (RDF) for EXPAREL manufactured using its 200-liter process. This decision impacts a previous $28.3 million recovery Pacira received and remands the case to the District Court to recalculate interest owed on other portions of the judgment.
- Counterparty
- Research Development Foundation
Pacira BioSciences M&A Deal with Viatris Inc.
Pacira BioSciences provided a status update on its pending acquisition by Viatris Inc., noting that the tender offer for $36.50 per share commenced on October 30, 2026. Due to the pending merger, the company will not release Q3 2026 earnings or hold a conference call, and it has withdrawn its previously issued 2026 financial guidance.
- Counterparty
- Viatris Inc.
Pacira BioSciences SVP, Finance Lauren Riker Sells $218K of Stock
Lauren Riker, SVP, Finance, sold 6,000 shares of Pacira BioSciences, Inc. at $36.32 a share, worth $218K in total on Oct 8, 2026. Shares held after the trade: 62,284 (-8.8%).
- Value
- $218K
- Shares
- 6,000
- Price
- $36.32
- Role
- SVP, Finance
- Holding change
- -8.8%
- Trade date
- Oct 8, 2026
Pacira BioSciences Signs $1.65B M&A Deal with Viatris Inc.
Pacira BioSciences entered into a definitive agreement to be acquired by Viatris Inc. for $36.50 per share in cash, representing an aggregate equity value of approximately $1.65 billion. The transaction will be executed via a cash tender offer and is expected to close by the end of 2026, positioning Viatris as a leader in non-opioid pain therapies.
- Value
- $1.65B
- Counterparty
- Viatris Inc.